Cetuximab concurrent with IMRT versus cisplatin concurrent with IMRT in locally advanced nasopharyngeal carcinoma: A retrospective matched case-control study.
To evaluate the treatment efficacies and toxicities of concurrent cetuximab-based bioradiotherapy (BRT) or cisplatin-based chemoradiotherapy (CRT) in locally advanced nasopharyngeal carcinoma. :Patients with previously untreated locally advanced nasopharyngeal carcinoma were matched into pairs, and enrolled into the study. All patients were given either BRT or CRT. Survival outcomes, toxicities, and prognostic factors were evaluated. :A total of 112 patients were enrolled. The 5-year overall survival was 79.3% and 79.5% in CRT and BRT arm, respectively (P = 0.797) and the 5-year DFS was 73.5% and 74.6%, respectively (P = 0.953). In toxicity analysis, CRT arm had more significant decrease in white blood cell, platelet, hemoglobin, and severe vomiting, while more severe skin reactions and mucositis were shown in BRT arm. :BRT was not less efficacious than traditional CRT. They lead to different aspects of toxicities. If patients cannot stand more severe toxicities caused by CRT, BRT could be an ideal alternative.
aState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University bNeurosurgery Department cChengdu, China.
Xin
X
Wu
Jingwen
J
Huang
Lei
L
Liu
Hongmei
H
Li
Ping
P
Li
Jing
J
Zhang
Li
L
Xie
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002277:Carcinoma; D016022:Case-Control Studies; D000068818:Cetuximab / Q000008:administration & dosage*; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D050397:Radiotherapy, Intensity-Modulated / Q000379:methods*; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult
D000970:Antineoplastic Agents; D000068818:Cetuximab; D002945:Cisplatin
Cancer Biomark. 2014;14(4):267-77
24934370
J Clin Oncol. 2001 Dec 1;19(23):4305-13
11731513
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):410-6
19427745
Oral Oncol. 2015 Sep;51(9):875-9
26163437
N Engl J Med. 2008 Sep 11;359(11):1116-27
18784101
J Natl Cancer Inst. 2005 Apr 6;97(7):536-9
15812080
J Clin Oncol. 2006 Mar 1;24(7):1072-8
16505426
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
26808342
Head Neck. 2001 Jul;23(7):579-89
11400247
Ann Oncol. 2012 May;23(5):1287-1292
21948811
J Clin Oncol. 2014 Sep 20;32(27):2940-50
25154822
Radiother Oncol. 2009 Feb;90(2):166-71
18977050
J Clin Oncol. 2005 Oct 1;23(28):6966-75
16192584
Oncologist. 2013;18(4):460-6
23576486
J Clin Oncol. 2010 Feb 20;28(6):911-7
20100966
Head Neck. 1998 Jul;20(4):320-7
9588705
Chemother Res Pract. 2012;2012:901320
23056941
Cancer Res. 1994 Jun 15;54(12):3153-9
8205534
J Clin Oncol. 2003 Feb 15;21(4):631-7
12586799
Acta Otolaryngol. 2007 Jun;127(6):651-7
17503236
Lancet Oncol. 2010 Jan;11(1):21-8
19897418
Oncogene. 1997 Jul 24;15(4):409-16
9242377
J Clin Oncol. 2007 Jun 1;25(16):2191-7
17538164
N Engl J Med. 2009 Apr 2;360(14):1408-17
19339720
Oncologist. 2005 Mar;10(3):215-24
15793225
J Cancer Res Clin Oncol. 2013 Jun;139(6):1063-71
23525586
Eur J Cancer. 2007 Jan;43(1):35-45
17098420
J Clin Oncol. 2003 Jan 1;21(1):92-8
12506176
Eur J Cancer. 2013 Jan;49(2):439-48
23116683
Strahlenther Onkol. 2012 Jan;188(1):42-8
22194029
Med Oncol. 2014 Sep;31(9):170
25119503
Anticancer Drugs. 2016 Jan;27(1):66-70
26352217
N Engl J Med. 2006 Feb 9;354(6):567-78
16467544
Lancet. 2009 May 2;373(9674):1525-31
19410716
J Clin Oncol. 2001 Mar 1;19(5):1350-7
11230478